The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders.
The prevalence of attention-deficit/hyperactivity disorder (ADHD) identified in an outpatient sample of 492 adults seeking mental health treatment was nearly 10 times higher than the prevalence identified in epidemiological studies, according to a poster presented at the recent 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD).
The authors, from the Penn State College of Medicine, wrote that the goal of the study was to examine the prevalence of ADHD in an adult outpatient setting and to examine the unique association between ADHD symptoms and functional impairment, controlling for co-occurring mental health concerns.
Despite the fact that approximately 4% of US adults are diagnosed with ADHD, there have been few studies of its prevalence and associated illness in clinical samples of adults seeking outpatient psychiatric care.
The sample was nearly 70% female and the mean age was 40; patients were starting mental health services. Researchers collected information on the total number of ADHD symptoms using the Adult ADHD Self-Report Scale (ASRS); the average score on the WHO Disability Assessment Schedule 2.0 for overall impairment; and co-occurring psychopathology on the DSM-5 Self-rated Level Cross-Cutting Symptom Measure.
Co-occurring psychopathology screening items included: depression, suicidality, mania, anxiety, sleep problems, and substance abuse. These scores were used as covariates.
ADHD symptoms contributed to the functional impairment of patients with a wide range of psychiatric symptoms. Age, depression, anxiety, substance abuse, mania, and sleep difficulty also explained a significant portion of variance in impairment, while gender and suicidality did not.
Using DSM-IV symptom count criteria (ie, 6+ inattention and/or hyperactivity/impulsivity symptoms), 40.85% of the sample met criteria for ADHD (110 inattentive, 24 hyperactive/impulsive, and 67 combined type). A total of 51.83% met DSM-5 symptom count criteria (125 inattentive presentation, 30 hyperactive/impulsive presentation, and 100 combined presentation).
The authors wrote that the results stress the need for further assessment of ADHD, including diagnostic interview and collateral rating, in standard mental health care for adults.
Reference
Babinski DE, Waxmonsky JG, Bixler EO, et al. Screening for ADHD and impairment in a general outpatient psychiatric sample of adults. Poster presented at the 2018 Annual Meeting of The American Professional Society of ADHD and Related Disorders; Washington, DC; January 12-14, 2018. Poster 32.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More